Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Other Operating Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Other Operating Expenses for 8 consecutive years, with $102.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $102.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $149.1 million, a N/A change, with the full-year FY2025 number at $8.2 million, up 154.04% from a year prior.
  • Other Operating Expenses was $102.2 million for Q4 2025 at Soleno Therapeutics, up from $43.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $102.2 million in Q4 2025 to a low of $3.0 million in Q1 2025.